0000905718-20-000907.txt : 20200828 0000905718-20-000907.hdr.sgml : 20200828 20200828105008 ACCESSION NUMBER: 0000905718-20-000907 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200828 DATE AS OF CHANGE: 20200828 EFFECTIVENESS DATE: 20200828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kintara Therapeutics, Inc. CENTRAL INDEX KEY: 0001498382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990360497 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-374369 FILM NUMBER: 201145801 BUSINESS ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 350-4364 MAIL ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: DelMar Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130123 FORMER COMPANY: FORMER CONFORMED NAME: Berry Only Inc. DATE OF NAME CHANGE: 20100805 D 1 primary_doc.xml X0708 D LIVE 0001498382 Kintara Therapeutics, Inc. 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA CALIFORNIA 92130 858-350-4364 NEVADA None DelMar Pharmaceuticals, Inc. Berry Only Inc. Corporation true Saiid Zarrabian 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Director Dennis Brown 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Scott Praill 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer John Liatos 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Director Robert Hoffman 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Robert Toth 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Laura Johnson 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Keith Murphy 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Steven Rychnovsky 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2020-08-19 false true true Series C Convertible Preferred Stock true Adgero Acquisition Corp., the Company's wholly-owned subsidiary merged with and into Adgero BioPharmaceuticals Holdings, Inc. ("Adgero"), with Adgero surviving the merger and becoming a wholly-owned direct subsidiary of the Company. 0 Aegis Capital Corp. 15007 None None 810 7TH AVENUE 18TH FLOOR NEW YORK NY NEW YORK 10019 All States true 30000000 21772000 8228000 false 161 3000000 true 0 true Assumes maximum commissions earned and over-allotment option exercised. Excludes expenses and value of up to 3,000 warrants received as compensation. 0 true Some of the proceeds may be used for general working capital, including the payment of salaries and other fees to those listed in Item 3. false Kintara Therapeutics, Inc. /s/ Scott Praill Scott Praill CFO 2020-08-28